small nuclear ribonucleoprotein polypeptide CGenealiases: U1C · Yhc1
Q-omics provides the consensus-scored SNRPC profile across patient tissues and cancer cell-line models. SNRPC expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, SNRPC is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, SNRPC protein abundance shows 31,395 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight LIHC, and HNSC as cancer lineages where SNRPC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNRPC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNRPC survival associations across molecular data types. SNRPC RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNRPC RNA expression–survival associations across cancer types. High SNRPC expression shows unfavorable associations in LIHC, KICH, KIRP, ACC, HNSC and LGG. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for SNRPC RNA expression.
This table summarizes SNRPC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SNRPC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNRPC shows higher tumor expression in HNSC, KIRC, COAD, LIHC, STAD and LUAD. The HNSC box plot shows higher SNRPC RNA expression in tumor versus normal tissue (log2 FC = +0.892, t-test p < 0.001).
This table shows molecular features associated with SNRPC in patient tissues and cancer cell lines. In patient samples, SNRPC shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, SNRPC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
